large_1200x800Welcome-to-SAHARA-LasVegas_O.webp

medium_1200x800Welcome-to-SAHARA-LasVegas_O.webp

small_1200x800Welcome-to-SAHARA-LasVegas_O.webp

thumbnail_1200x800Welcome-to-SAHARA-LasVegas_O.webp

1200x800Welcome-to-SAHARA-LasVegas_O.webp

2023 Inflammatory Disease Summit

PA/NP Exclusive Event Leading into Fall Clinical

large_hotel.jpg

medium_hotel.jpg

small_hotel.jpg

thumbnail_hotel.jpg

hotel.jpg

2024 Winter Clinical Dermatology Conference - Miami

47.2 percent received no treatment on day of diagnosis; by one year, 71.8 percent were not receiving treatment

Study Looks at Treatment Patterns for Alopecia Areata

Independent association with CMD seen for higher PASI, longer disease duration, psoriatic arthritis, hypertension

Coronary Microvascular Dysfunction ID'd in 31.5 Percent With Psoriasis

No difference seen in efficacy for NB-UVB treatment combined with tacrolimus 0.1 percent or calcipotriol/betamethasone dipropionate

 Combo Treatments Efficacious for Generalized-Type Vitiligo

HS lesions insensitive to innocuous cold and warmth, noxious heat, and light touch compared with healthy pain-free controls

Somatosensory Profiles Characterized in Hidradenitis Suppurativa

Vitiligo affects patients' daily lives and well-being; more than half of patients report diagnosed mental health conditions

Vitiligo Has Considerable Impact on Mental Health

Differences also seen for microbiomes in those with early- and late-stage melanoma, including higher alpha diversity in early-stage

Fecal Microbiota Profile Differs for Melanoma, Healthy Controls

Similar patterns also observed in C-section-born infants

Alterations in Infant Gut Microbiota Precede Development of Eczema

Navigating the emotional and social challenges and enhancing support strategies for patients with vitiligo

Psychosocial Impact of Vitiligo

Risk varies by age, atopic dermatitis severity, and inflammatory bowel disease subtype

Atopic Dermatitis Increases Risk for Inflammatory Bowel Disease

Important Update

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors

In this installment of Discourses in Dermatology, Dr. George Han, Director of Clinical Research at Northwell Health in New York, sits down with Dr. Andrew Blauvelt, Investigator at Oregon Medical Research Center, to discuss the genetic, environmental, and lifestyle factors that influence psoriasis. They also explore the comorbidities associated with psoriasis and how they play into the role of psoriatic disease.The role of genetics in psoriasisDr. Han begins by asking Dr. Blauvelt what role genetics really plays in the development of psoriasis.Dr. Blauvelt references the first genetic study published on psoriasis, spearheaded by Danish researchers in the Faroe Islands in 1963, which found evidence of a genetic component to psoriasis in the local island population. &nbsp;He also comments on a key study examining identical twins that revealed strong evidence in favor of a genetic component to psoriasis.Dr. Blauvelt notes that while there is a genetic component to psoriasis, it’s not a Mendelian disease. Rather, there are 70 to 80 susceptibility genes that have been identified that either confer a risk for psoriasis or confer some protection.With those factors considered, he explains to his patients that while there is indeed a significant genetic component, it does not account for the entire picture of psoriasis. He estimates that approximately 40% of patients have a family history of the condition but suggests that even those without a family history may still have a genetic predisposition due to a combination of genes inherited from their parents.&nbsp;To summarize, he reiterates that psoriasis is a complex condition with a genetic component with other factors also involved in its development.Key points<ul><li>A seminal study demonstrating the genetics of psoriasis was conducted by Danish researchers on the Faroe Islands in 1963</li><li>Twin studies have also revealed strong evidence in favor of a genetic component to psoriasis</li><li>Psoriasis is not a Mendelian disease, but is influenced by 70 to 80 susceptibility genes</li><li>While there is a significant genetic component to psoriasis, it does not account for the entire picture</li></ul>Environmental influences on psoriasisDr. Han continues the conversation by asking Dr. Blauvelt about the environmental influences on psoriasis that may encourage psoriasis in susceptible individuals.Dr. Blauvelt replies by giving more background on the genetics of psoriasis, explaining that there are 2 types of psoriasis as it relates to genetics. The first type is a result of genes that tend to run in families, with HLA-Cw6 being the most common. With this type, there is usually an earlier onset in the late teens or early 20s.&nbsp;The second type tends to manifest in the early 40s, and those patients tend not to have a family history of the condition. Rather, this type of psoriasis tends to be more associated with metabolic syndrome, diabetes, or hypertension.Dr. Blauvelt then begins delving into some of the well-known influences on psoriasis, including stress, infections like strep throat, and certain medications. He specifically mentions lithium and interferon stimulators, remarking that Aldara cream can stimulate psoriasis locally.He comments that the most common influences on psoriasis he has seen in his career have been strep throat, stress, and cold weather. He advises patients that any kind of stressor on the body, whether emotional or physical stress from temperature, medication, or infection, can trigger the psoriasis immune response.Key points<ul><li>Influences on psoriasis can include stress, infections, and certain medications</li><li>Lithium and interferon stimulators can affect psoriasis</li><li>Cold weather can also trigger the psoriasis immune response</li></ul>Comorbidities of psoriasisDr. Blauvelt comments that the list of comorbidities associated with psoriasis has become quite long and can be overwhelming for healthcare providers who are unsure how to counsel patients on this topic.He describes his approach to speaking with patients and how he always discusses the 2 most important psoriasis comorbidities, psoriatic arthritis and heart disease, at their first visit. When discussing psoriatic arthritis, he explains that it is the most common comorbidity and will affect treatment choice, and that is an important facet for patients to consider and understand. In his experience, some patients with psoriasis are unaware that they are at risk for arthritis and thus it should be discussed early on.Dr. Blauvelt also makes sure to discuss heart disease with his patients and emphasize the seriousness of it. He references the literature that is now available on psoriasis as an independent risk factor for heart disease and says it also suggests that the risk of heart disease can be reduced if an impact can be made on the skin.He mentions large databases that suggest TNF blockers may reduce the risk of cardiovascular events but that we don’t yet have that same kind of data for IL-17s and IL-23s. He also references studies conducted at the NIH that put patients on biologics for one year and measured their atherosclerotic plaques. Those studies demonstrated that IL-17 blockers were the best class of drugs in terms of improving atherosclerosis in patients with psoriasis. While they don’t prevent heart attack and stroke, it’s strong evidence that these therapies are having positive outcomes.Key points<ul><li>The long list of comorbidities associated with psoriasis can make it overwhelming to counsel patients</li><li>The 2 most important comorbidities to discuss with patients are psoriatic arthritis and heart disease</li><li>Psoriatic arthritis should be discussed with patients at their first visit, since it’s the most common comorbidity and can affect treatment choice</li><li>Literature suggests that psoriasis is an independent risk factor for heart disease and that the risk of heart disease can be reduced if an impact can be made on the skin</li><li>Large databases suggest TNF blockers may reduce risk of cardiovascular events</li><li>NIH studies demonstrated that IL-17 blockers were the best class of drugs in improving atherosclerosis in patients with psoriasis</li></ul>Mental health as a comorbidity of psoriasisDr. Han continues the conversation by asking Dr. Blauvelt his thoughts on mental health and psoriasis and how he approaches this discussion with patients.Dr. Blauvelt references his involvement in one of the first multidisciplinary clinics for psoriasis in the United States that included dermatology, rheumatology, and psychiatry. When he asked patients about their mental health, they often reported they were depressed and anxious due to the condition. He found many were hesitant to be referred to the psychiatry clinic because they felt that if their psoriasis cleared, their mental health would improve, which demonstrates there is a component to the condition that can cause angst and depression.He remarks that practitioners can assume quality of life is impaired for patients with psoriasis and that patients are likely to score poorly on quality-of-life measures and depression scales. He emphasizes that this should not be ignored and that it’s important to listen to patients and monitor for signs of severe depression and suicidal ideation.&nbsp;Dr. Han concludes by agreeing on the importance of listening and caring for the whole patient.Key points<ul><li>There is a component to psoriasis that can cause angst and depression among patients with the condition</li><li>Patients with psoriasis will often have impaired quality of life and score poorly on quality-of-life measures and depression scales</li><li>It’s vital to listen to patients and monitor them for signs of severe depression and suicidal ideation</li></ul>

Can patients treated with spesolimab receive live vaccines? 

How have the emergence of nonsteroidal topical options in recent years impacted your practice? 

What are some lesser-known factors that can increase the risk of developing SCC?

In episode 60 of Derms and Conditions, our host, James Q. Del Rosso, DO, sits down with Cheri Frey, MD, the residency program director of dermatology at Howard University. The 2 discuss how to address skin care with patients and key products that should be incorporated into a skin care routine for specific skin types and populations.

Cheri Frey, MD

dermsquared-derms-conditions-podcast-thumbs.png

Derms and Conditions Podcast

A Closer Look at How to Address Skin Care With Your Patients

In Episode 59 of Derms and Conditions, our host, James Q. Del Rosso, DO, continues his conversation with Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale University School of Medicine who performs specialized research on novel treatments and therapies.&nbsp;

Christopher Bunick, MD, PhD

Improving Our Understanding of How Drugs Work: Clarifying Questions with Monoclonal Antibodies and JAK Inhibitors

In episode 58 of Derms and Conditions, our host, Dr James Q. Del Rosso, presents a self-made episode where he discusses some clarifications regarding commonly misunderstood therapies in dermatology.&nbsp;

Removing the Confusion Surrounding Some Commonly Used Therapies

Join the leading experts as they go in-depth on some of the most important topics in dermatology. In this special feature, they give their invaluable insights into the mechanism of disease of psoriasis.

Discourses in Dermatology

Discourses in Dermatology - Genetics Comorbidities (Video 2)

Welcome to Dermbits! Watch short videos of KOLs answering your questions

Important Update

The new destination for dermatology clinicians

Compelling clinical cases

Listen to our experts on the go

Hear what the experts are saying

Latest Expert Videos